Brief: Advicenne: Commercialization Agreement With FrostPharma For Sibnayal

Advicenne SA

04/01/2022 06:06

Jan 4 (Reuters) - Advicenne SA  ADVIC.PA :
    * ADVICENNE ANNOUNCES COMMERCIALIZATION AGREEMENT WITH
FROSTPHARMA
AB FOR SIBNAYAL™ IN THE NORDIC REGION
    * ADVICENNE WILL RECEIVE A TRANSFER PRICE AND ROYALTIES FOR
AN
AMOUNT MARKEDLY HIGHER THAN 50% OF FUTURE SALES OF SIBNAYAL
    * SIBNAYAL™ WILL BE MARKETED TO ONE-THIRD OF EUROPEAN
PATIENTS BY
THREE MEMBERS OF EXCLUSIVE 'YOUR PHARMA PARTNER' NETWORK
    * UNDER TERMS OF AGREEMENT, FROSTPHARMA WILL RECEIVE
EXCLUSIVE
MARKETING RIGHTS TO SIBNAYAL™ FOR TREATMENT OF DRTA IN ITS
RESPECTIVE MARKET
    * AS PART FROM THE AGREEMENT, FROSTPHARMA IS ALSO MANAGING
THE
EARLY ACCESS PROGRAM RUNNING FOR SIBNAYAL™ IN SWEDEN

Source text for Eikon:  ID:nBw47TS8fa 
Further company coverage:  ADVIC.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))